Newton Biocapital heads for year-end close for second, EUR 150m life sciences fund
Newton Biocapital, a Belgian-Japanese venture capital firm focused on life sciences, is heading for a EUR 150m close for its second fund by year-end, and is open to commitments from institutional investors, managing partner Pierre Detrixhe and scientific director Tomoko Asaoka told Unquote.
More on Funds
Golding aims to raise EUR 350m for next buyout co-investment fund amid ‘unprecedented’ dealflow
Vehicle expects to make its first deals this year, providing additional equity for deals against a tough fundraising backdrop
Moonfire Ventures raises USD 115m to back early-stage startups in Europe
AI-powered VC firm has raised USD 90m for Fund II and USD 25m for its Opportunity Fund to double down on winners
Hamilton Lane targets global impact opportunities with new USD 370m fund
Asset manager’s new fund will make direct investments and can take larger stakes than its USD 95m predecessor
LP Profile: Lennertz & Co gears up for new tech impact venture fund-of-funds
German family office’s new strategy is set to launch this year with a EUR 50m-EUR 100m target
Latest News
Golding aims to raise EUR 350m for next buyout co-investment fund amid ‘unprecedented’ dealflow
Vehicle expects to make its first deals this year, providing additional equity for deals against a tough fundraising backdrop
Permira to acquire majority stake in Gruppo Florence
Existing shareholders including VAM Investments and management of the Italian fashion group will reinvest, while Italmobiliare will exit
Mimir Group ramps up global origination effort with London office and focus on life science carve-outs
Stockholm-based investor is considering divestments, although challenging market remains a barrier
Gyrus Capital acquires LRE Medical from KPS-backed AIS Global
Carve-out of German diagnostic equipment manufacturer comes over two years after first sale attempt